▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Jia Jie Chen

JiaJieChen

Recent Articles by Jia Jie Chen

getty-lab-tech-vials

Apr 23, 2021 by Jia Jie Chen

With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?

The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?

getty-woman-call-pharmacist

Apr 21, 2021 by Jia Jie Chen

1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?

The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?

getty-hearing-loss

Apr 16, 2021 by Jia Jie Chen

Are Disappointing Results an Opportunity for Frequency Therapeutics Investors?

A risky path lies ahead for the clinical-stage biotech, which saw disappointing results for FX-322 in March 2021. Can management learn from its mistakes?

getty-female-dermatologist

Apr 12, 2021 by Jia Jie Chen

With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?

A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.

gettty-close-up-woman-eyes

Apr 7, 2021 by Jia Jie Chen

An End to This Rare Syndrome Could Be an Opportunity for Investors

A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month.

getty-lab-tech-vials

Apr 1, 2021 by Jia Jie Chen

Is Sarepta Therapeutics Worthy of Redemption?

A potentially misinterpreted clinical trial readout from January may mean a market opportunity for bargain hunters.

medicalteam580-SPNMJX

Mar 31, 2021 by Jia Jie Chen

The Promises Behind Terns' Multi-Pronged Pipeline

This pharma may be a newcomer to the stock market, but it has several innovative drugs in development for a common condition with no current treatments approved.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services